RT Journal Article
SR Electronic
T1 Osteopontin levels in sputum supernatant and serum of patients with lung cancer: Does coexistent COPD make the difference?
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P4192
VO 42
IS Suppl 57
A1 Vaso Petta
A1 Stelios Loukides
A1 Konstantinos Kostikas
A1 Georgios Papatheodorou
A1 Zoi Tsilogianni
A1 Spyridon Papiris
A1 Nikolaos Koulouris
A1 Petros Bakakos
A1 Stelios Loukides
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P4192.abstract
AB Introduction: Osteopontin (OPN) is a multifunctional cytokine that has been involved in tumor progression and angiogenesis of lung cancer. Lung cancer (LC) and COPD are both smoking-related diseases and may share common pathogenetic mechanisms; however the role of OPN in the pathogenesis of both diseases, has not been elucidated yet.Objective: We aimed to determine the levels of OPN in sputum supernatants and serum of patients with LC with and without COPD and to evaluate its performance as a prognostic biomarker in these patients.Methods: Seventy three consecutive patients with LC (43 with COPD) were included in the study. All subjects underwent lung function tests, sputum induction for OPN, VEGF, TGF-β1 and IL-8 and serum collection for OPN measurement; All patients were optimally treated for LC and COPD according to their attending physicians and were followed for one year or until death.Results: Serum OPN was significantly higher in patients with concomitant LC and COPD compared to LC alone (median IQR 47[28-96] vs 37 [27-60], pg/ml, p<0.05). No other significant differences were observed between the two groups. In ROC analysis, serum OPN presented a modest performance for the prediction of one-year survival in patients with LC and COPD [AUC 0.698]. Increased serum OPN levels [>39pg/ml] in patients with LC and coexistent COPD were associated with a higher risk of death in one-year follow up [log-rank test, p=0.002].Conclusions: Serum OPN is higher in the presence of COPD in patients with LC. Serum OPN is a good predictor of survival in patients with LC and COPD but could not predict one year survival in patients with LC without COPD.